Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice

Reproductive Toxicology

Volumn 73, Issue , 2017, Pages 362-371

  Barrow, Paul ^a   Villabruna, Loris ^a   Hoberman, Alan ^b   Bohrmann, Bernd ^a   Richter, Wolfgang F ^a   Schubert, Christine ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Dart; Disease model; Monoclonal antibody; PS2APP mouse; Safety testing

Indexed keywords

GANTENERUMAB; PLACEBO; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PRESENILIN 2; PSEN2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DEVELOPMENTAL TOXICITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FOOD INTAKE; LOW DRUG DOSE; MALE; MATING; MOUSE; MOUSE MODEL; NONHUMAN; POSTNATAL DEVELOPMENT; PRENATAL DEVELOPMENT; REPRODUCTIVE TOXICITY; TOXICOKINETICS; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG EFFECT; EMBRYO DEVELOPMENT; FERTILITY; FETUS; FETUS DEVELOPMENT; GENETICS; IMMUNOLOGY; MAMMALIAN EMBRYO;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; FEMALE; FERTILITY; FETAL DEVELOPMENT; FETUS; IMMUNOGLOBULIN G; MALE; MICE, TRANSGENIC; PRESENILIN-2;

EID: 85026513898     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2017.07.014     Document Type: Article

References (34)

1. The Alzheimer's Association, The Alzheimer's Association. 2016 http://www.alz.org/, (Accessed August 8, 2016).
2. Alzheimer's Disease International, Policy Brief for Heads of Government The Global Impact of Dementia 2013–2050. 2013 http://www.alz.co.uk/research/GlobalImpactDementia2013. pdf, (Accessed August 8, 2016).
3. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999), 173–177.
4. Citron, M., Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004), 677–685.
5. Novakovic, D., Feligioni, M., Scaccianoce, S., Caruso, A., Piccinin, S., Schepisi, C., Errico, F., Mercuri, N.B., Nicoletti, F., Nisticò, R., Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des. Devel. Ther. 7 (2013), 1359–1364.
6. Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W.F., Gantenerumab: a novel human anti-A(antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J. Alzheimers Dis. 28 (2012), 49–69.
7. Dubois, B., Feldman, H.H., Jacova, C., DeKosky, S.T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, P.J., Scheltens, P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS?ADRDA criteria. The Lancet Neurology 6 (2007), 734–746.
8. Ryman, D.C., Acosta-Baena, N., Aisen, P.S., Bird, T., Danek, A., Fox, N.C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J.B.S., Lopera, F., Martins, R., Masters, C.L., Mayeux, R.P., McDade, E., Moreno, S., Reiman, E.M., Ringman, J.M., Salloway, S., Schofield, P.R., Sperling, R., Tariot, P.N., Xiong, C., Morris, J.C., Bateman, R.J., Network A. t. D.I.A. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83 (2014), 253–260.
9. ClinTrials. gov, Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU). 2016 https://www.clinicaltrials.gov/ct2/show/NCT01760005, (Accessed 06 February, 2017).
10. Kelleher, R.J., Shen, J., Presenilin-1 mutations and Alzheimer's disease. Proc. Natl. Acad. Sci. 114 (2017), 629–631.
11. ClinTrials.gov,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease. https://clinicaltrials.gov/ct2/show/record/NCT01224106, (accessed August 9, 2016).
12. Lasser, R., Ostrowitzki, S., Scheltens, P., Boada, M., Dubois, B., Dorflinger, E., Balas, B., Nikolcheva, T., Volz, D., Ashford, E., Edgar, C., Garibaldi, G., Fontoura, P., Santarelli, L., Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: results from scarlet road-a global, multicenter trial. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 11 (2016), 331–332.
13. Scheltens, P., Nikolcheva, T., Lasser, R., Ostrowitzki, S., Boada, M., Dubois, B., Dorflinger, E., Volz, D., Eichenlaub, U., Rabe, C., Bittner, T., Schmitz, M., Edgar, C., Garibaldi, G., Fontoura, P., Santarelli, L., Biomarker data from scarlet road: a global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. Alzheimer's Dementia: J Alzheimer's Assoc., 11, 2015, 331.
14. Weinbauer, G.F., Luft, J., Fuchs, A., The Enhanced Pre-and Postnatal Development Study for Monoclonal Antibodies In Teratogenicity Testing. 2013, Barrow, C.P., Ed. Springer, Totowa, NJ, 185–200.
15. ICH, Harmonised Tripartite Guideline: Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals. S6(R1). 2011 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf, (accessed February 17, 2016).
16. Chapman, K.L., Pullen, N., Andrews, L., Ragan, I., The future of non-human primate use in mAb development. Drug Discov. Today 15 (2010), 235–242.
17. Richards, J.G., Higgins, G.A., Ouagazzal, A.-M., Ozmen, L., Kew, J.N.C., Bohrmann, B., Malherbe, P., Brockhaus, M., Loetscher, H., Czech, C., Huber, G., Bluethmann, H., Jacobsen, H., Kemp, J.A., PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-Related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci. 23 (2003), 8989–9003.
18. Yamada, M., Tsukagoshi, H., Otomo, E., Hayakawa, M., Systemic amyloid deposition in old age and dementia of Alzheimer type: the relationship of brain amyloid to other amyloid. Acta Neuropathol. 77 (1988), 136–141.
19. ICH, Harmonised Tripartite Guideline: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R2). 2005 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5/Step4/S5_R2__Guideline.pdf, (accessed August 15, 2016).
20. Snedecor, G., Cochran, W., Variance Test for Homogeneity of the Binomial Distribution. 6th ed., 1967, Iowa State University Press, Ames, 240–241.
21. Sokal, R.R., Rohlf, F.J., Bartlett' S Test of Homogeneity of Variances. In The Principles and Practice of Statistics in Biological Research. 1969, WH Freeman and Co, San Francisco, 240–241.
22. Snedecor, G., Cochran, W., Analysis of Variance. 6th ed., 1967, Iowa State University Press, Ames, 258–298.
23. Dunnett, C.W., A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50 (1955), 1096–1121.
24. Sokal, R.R., Rohlf, F.J., Kruskal-Wallis Test. In The Principles and Practice of Statistics in Biological Research. 1969, WH Freeman and Co, San Francisco, 388–391.
25. Dunn, O.J., Multiple comparisons using rank sums. Technometrics 6 (1964), 241–252.
26. Siegel, S., The Fisher's Exact Probability Test In Nonparametric Statistics for the Behavioral Sciences. 1956, McGraw-Hill Co, New York, 96–105.
27. Littell, R.C., Stroup, W.W., Freund, R.J., SAS for Linear Models. 4th ed., 2002, SAS institute, Cary, North Carolina.
28. Riley, E.P., Foss, J.A., The acquisition of passive avoidance, active avoidance, and spatial navigation tasks by animals prenatally exposed to cocaine. Neurotoxicol. Teratol. 13 (1991), 559–564.
29. Murray, J.M., Thompson, A.M., Vitsky, A., Hawes, M., Chuang, W.-L., Pacheco, J., Wilson, S., McPherson, J.M., Thurberg, B.L., Karey, K.P., Andrews, L., Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: the utility of animal models of disease in the toxicological evaluation of potential therapeutics. Mol. Genet. Metab. 114 (2015), 217–225.
30. Marsden, E., Leroy, M., Teratology Studies in the Mouse. In Teratogenicity Testing, Methods and Protocols. Barrow, C.P., (eds.), 2013, Humana Press, Totowa, NJ, 10.1007/978-1-62703-131-8_10pp 111–123.
31. Jarvis, P., Srivastav, S., Vogelwedde, E., Stewart, J., Mitchard, T., Weinbauer, G.F., The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations. Birth Defects Res. B Dev. Reprod. Toxicol. 89 (2010), 175–187.
32. DeSesso, J.M., Williams, A.L., Ahuja, A., Bowman, C.J., Hurtt, M.E., The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit. Rev. Toxicol. 42 (2012), 185–210.
33. Bowman, C.J., Martin, P.L., Developmental and Reproductive Safety Assessment of Biopharmaceuticals. In Developmental and Reproductive Toxicology. A Practical Approach. Hood, R.D., (eds.), 3 ed., 2012, CRC Press, Boca Raton, 479–490.
34. Bowman, C.J., Breslin, W.J., Connor, A.V., Martin, P.L., Moffat, G.J., Sivaraman, L., Tornesi, M.B., Chivers, S., Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis. Birth Defects Res. B Dev. Reprod. Toxicol. 98 (2013), 459–485.